{
    "clinical_study": {
        "@rank": "159754", 
        "arm_group": {
            "arm_group_label": "Sodium Bicarbonate", 
            "arm_group_type": "Experimental", 
            "description": "Oral sodium bicarbonate tablets administered at a starting dose of 0.6 mEQ/Kg body weight and dose will be increased after evaluation every 4 weeks.\nWeekly schedule:\n0-4 weeks: Serial Measurement at baseline, without therapy\n4-8 weeks: *~0.6 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing\n8-12 weeks: *~0.9 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing\nto the closest dose of 650 mg (7.74 mEq)"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to assess the effect of alkali administration on bicarbonate\n      and potassium levels in patients with Sickle Cell Disease (SCD) and depressed serum\n      bicarbonate levels. The study is a prospective non-blinded evaluation of tolerability and\n      efficacy of alkali repletion with 4 weeks of observation and two sequential 4 week courses\n      of escalating oral sodium bicarbonate treatment."
        }, 
        "brief_title": "Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Sickle Cell Anemia", 
            "Chronic Kidney Disease", 
            "Metabolic Acidosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acidosis", 
                "Anemia", 
                "Anemia, Sickle Cell", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Sickle cell patients with HbSS.\n\n          -  eGFR <90 ml/min/1.73m2(determined by abbreviated 4 variable modification MDRD\n             equation) and/or measured urinary albumin to creatinine ratio > 30mg/g.\n\n          -  Age \u226518 years\n\n        Exclusion Criteria:\n\n          -  Previous chronic treatment with alkali (including sodium bicarbonate, calcium\n             carbonate or baking soda)\n\n          -  Bicarbonate level >25 mEq/L\n\n          -  Decompensated heart failure\n\n          -  Uncontrolled systolic blood pressure >140 mm/Hg (the cutoff for systolic hypertension\n             in SCD is lower than in non-SCD)\n\n          -  Moderate-to-severe lower extremity edema\n\n          -  Projected progression to ESRD within 6 months\n\n          -  Kidney transplantation\n\n          -  VOC within 1 week of study entry\n\n          -  Active (open) leg ulcer\n\n          -  Change in hydroxyurea dose within the last 3 months, unless a self-limited\n             interruption of a stable dose\n\n          -  Blood transfusion within 8 weeks, unless on chronic transfusions Pregnancy\n\n          -  Inability to give informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01894594", 
            "org_study_id": "09-12-13"
        }, 
        "intervention": {
            "arm_group_label": "Sodium Bicarbonate", 
            "intervention_name": "Sodium Bicarbonate", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Sickle cell disease", 
            "Chronic kidney disease", 
            "Bicarbonate therapy"
        ], 
        "lastchanged_date": "July 9, 2013", 
        "location": {
            "contact": {
                "last_name": "Jane Little, MD", 
                "phone": "216-844-5868"
            }, 
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44106"
                }, 
                "name": "University hospitals Case Medical Center"
            }, 
            "investigator": {
                "last_name": "Jane Little, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Alkali Therapy in Subjects With Sickle Cell Disease (SCD) - Evaluation of Efficacy, Safety, and Beneficial Effects", 
        "other_outcome": {
            "description": "To assess the influence of alkali administrations on markers of kidney tubule inflammation.", 
            "measure": "Tubular effect", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "overall_contact": {
            "last_name": "Jane Little, MD", 
            "phone": "216-844-5868"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Case Medical Center", 
            "last_name": "Jane Little, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess the effect of alkali administration on bicarbonate and potassium levels in patients with SCD and depressed serum bicarbonate levels.", 
            "measure": "Serum bicarbonate level", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01894594"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital Case Medical Center", 
            "investigator_full_name": "Jane Little", 
            "investigator_title": "Director, Sickle cell disease program", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To assess the effect of alkali administration on improvement in hemolysis and on sequelae of impaired kidney function, ie, LDH, Hgb, reticulocyte count, red cell half-life, and muscle strength, Vitamin D levels, and  markers of bone turnover, respectively.", 
            "measure": "Hemolysis markers", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "University Hospital Case Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital Case Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}